Related Experiment Video
Updated: Aug 11, 2026
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Expression of IFITM1 in chronic myeloid leukemia patients
Cemaliye Boylu Akyerli1, Meral Beksac, Michelle Holko
1Department of Molecular Biology and Genetics, Bilkent University, Bilkent, 06800 Ankara, Turkey.
Insights
Interferon induced transmembrane protein 1 (IFITM1) gene expression in chronic myeloid leukemia (CML) patients differs significantly between risk groups. Higher IFITM1 levels correlate with better survival outcomes in CML.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Accurate prognostic scoring is crucial for CML patient management.
- Interferon induced transmembrane protein 1 (IFITM1) plays a role in cell signaling.
Purpose of the Study:
- To investigate the gene expression profile of IFITM1 in CML patients.
- To correlate IFITM1 expression with the New Prognostic Score (NPS) in CML.
- To assess the relationship between IFITM1 expression and patient survival.
Main Methods:
- Peripheral blood samples were collected from sixty CML patients.
- Gene expression levels of IFITM1 were quantified using real-time reverse transcription polymerase chain reaction (RT-PCR).
- Patients were classified into high- and low-risk groups based on the NPS.
Main Results:
- A significant difference in IFITM1 expression was observed between high- and low-risk CML groups (P = 9.7976 x 10(-11)).
- Higher IFITM1 expression levels were associated with improved patient survival (P = 0.01).
Conclusions:
- IFITM1 expression profiling can serve as a molecular tool for classifying CML.
- IFITM1 expression may be a predictive biomarker for survival in chronic myeloid leukemia patients.
Abstract:
We investigated the peripheral blood gene expression profile of interferon induced transmembrane protein 1 (IFITM1) in sixty chronic myeloid leukemia (CML) patients classified according to new prognostic score (NPS). IFITM1 is a component of a multimeric complex involved in the trunsduction of antiproliferative and cell adhesion signals. Expression level of IFITM1 was found significantly different between the high- and low-risk groups (P = 9.7976 x 10(-11)) by real-time reverse transcription polymerase chain reaction (RT-PCR). Higher IFITM1 expression correlated with improved survival (P = 0.01). These results indicate that IFITM1 expression profiling could be used for molecular classification of CML, which may also predict survival.
